Super Generics Market: The Untapped Gold Mine

The Super Generics industry has enjoyed a remarkable run over the past two decades. The vast healthcare cost-saving potential of these therapies has accelerated their adoption and proven the immense potential that generics have to reach wider patient segments. The super generic drugs market is estimated to be worth $38 billion in 2019 and is expected to grow at CAGR of 12% during the forecast period.

The availability of several advanced drug development and technology platforms have enabled the fabrication and formulation of improved versions of existing drug products. Such modified pharmacological interventions are commonly referred to as super generics/ complex generics / value-added generics. Although super generics are based on the same mechanism of action as that of the original drug, these versions usually have certain additional attributes, such as a new active ingredient, improved manufacturing process, alternative dosage regimen, modified release properties or different formulation. 

With 780 generics approved and 85% annual prescription going to generics in US market alone - suggests a jump in the generics market

The problems arrive:

While the generics market is highly attractive, the increasing competition in this domain has decreased the profit margins of each player and has pushed the developers to actively look for alternate opportunities in this segment.

the challenges for Generics market includes increased competition, price erosion and low profit margins

Innovation is the solution:

The low-cost potential of generics combined with the innovation of novel drugs has led to the rise of supergenerics. The term supergenerics is used for novel treatments and treatment modalities, derived from existing off-patent small-molecule drugs. The high growth prospect of these therapies has attracted various stakeholders in this space.

Opportunity in Supergenerics Market is seen as over 130 generics launched and 85 tech platforms deployed in the segment

Given lucrative cost benefits and marketing exclusivity, supergeneric medicines represent an attractive product segment within the modern pharma industry; upcoming patent expiries of blockbuster drugs have intensified the interest in this field.

Novel technology developers are driving innovation:

Upcoming technologies are increasingly exploiting strategies for the development of supergenerics; the US is currently considered to be the base of operations for the majority of such companies.

Supergeneric Development Technology Providers geographical landscape analysis shows global growth

Driven by expansion into diverse therapeutic areas and exploitation of different routes of delivery, the long term opportunity in this market is likely to evolve at CAGR of ~17%.